Thus, the results suggest that the modification with human endoglin targeting scFv and the replacement of the encapsulated dye with therapeutic cargos such as chemotherapeutic drugs, nucleotides or immune modulating therapeutics is a promising approach for the future modulation of the tumor stroma of cancer patients by simultaneous targeting of FAP and endoglin. The gene discussed is ENG; the disease is neoplasm.